1. Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib.
Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Specimens underwent targeted NGS using the MGH NGS assay or the FoundationOne platform. Only genes with at least one genetic alteration detected in resistant specimens are depicted. If a particular gene was not evaluated in a given specimen due to the type of sequencing platform used, it is represented in dark gray. Within this cohort, the most commonly mutated genes were ALK and TP53. Recurrent alterations in other genes were uncommon. In addition, six ceritinib-resistant, patient-derived cell lines underwent NGS using a 1,000-gene panel (see Genotype Assessments in Methods). Genes from this panel are shown if the following criteria are met: (i) a genetic alteration was present in at least one of the patient-derived cell lines, and (ii) the gene was also included in either the MGH NGS or FoundationOne panels. Please see Supplementary Table S11 for a comprehensive assessment of all genetic alterations identified within these cell lines.
Justin F. Gainor et al. Cancer Discov 2016;6:
©2016 by American Association for Cancer Research